Compare · EKSO vs TMO
EKSO vs TMO
Side-by-side comparison of Ekso Bionics Holdings Inc. (EKSO) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EKSO and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $176.13B, about 4188.8x EKSO ($42.0M).
- Over the past year, EKSO is up 157.8% and TMO is up 18.4% - EKSO leads by 139.4 points.
- TMO has been more active in the news (19 items in the past 4 weeks vs 16 for EKSO).
- TMO has more recent analyst coverage (25 ratings vs 0 for EKSO).
- Company
- Ekso Bionics Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $11.37-1.52%
- $473.94-1.69%
- Market cap
- $42.0M
- $176.13B
- 1M return
- +22.26%
- +2.47%
- 1Y return
- +157.82%
- +18.44%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 16
- 19
- Recent ratings
- 0
- 25
Ekso Bionics Holdings Inc.
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, sells, and rents exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, sells, and rents exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation and OttoBock Healthcare Product GmbH. The company was founded in 2005 and is headquartered in Richmond, California.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest EKSO
- Amendment: Ekso Bionics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Cummins Wes was granted 200,000 shares (SEC Form 4)
- Director Miller Douglas S was granted 200,000 shares (SEC Form 4)
- Director Benson Ella G. was granted 200,000 shares (SEC Form 4)
- Director Nottenburg Richard N was granted 200,000 shares (SEC Form 4)
- Chief Financial Officer Wong Jerome was granted 40,000 shares, increasing direct ownership by 161% to 64,771 units (SEC Form 4)
- Director Davis Scott G. was granted 109,357 shares, increasing direct ownership by 139% to 188,134 units (SEC Form 4)
- Director Clancy William M was granted 200,000 shares (SEC Form 4)
- SEC Form 3 filed by Ekso Bionics Holdings Inc.
- SEC Form 3 filed by Ekso Bionics Holdings Inc.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)